ToolGen Incorporated
A biotech firm licensing genome editing patents for therapeutics and agriculture.
199800 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙로 172 바이오이노베이션파크,8층, 강서구
- Website:
- http://www.toolgen.com/eng
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
ToolGen Incorporated is a biotechnology company specializing in the development and application of genome editing technology. A pioneer in the field since 1999, the company has developed three successive generations of gene editing tools: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and the CRISPR-Cas9 system. ToolGen holds foundational patents for CRISPR-Cas9 technology, claiming to be the first to file a patent for its use in eukaryotic cells. The company's business model is centered on three core areas: monetizing its intellectual property through licensing and collaboration, developing proprietary therapeutic programs in gene and cell therapy, and applying its technology to improve agricultural crops.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ToolGen Incorporated and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
No filings match the current criteria. |
Automate Your Workflow. Get a real-time feed of all ToolGen Incorporated filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ToolGen Incorporated via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |